verified SJR 1,856 · Q1 • database Scopus / SJR & Web of Science indexed

United Kingdom · Elsevier Ltd

workspace_premium Q1 — Medicine (miscellaneous) lock_open Open Access Unclaimed

Value in Health

Value in Health is a journal indexed in SJR in Medicine (miscellaneous) and Public Health, Environmental and Occupational Health with an H index of 138. It has an SJR impact factor of 1,856 and it has a best quartile of Q1. It is published in English. It has an SJR impact factor of 1,856.

Value in Health focuses its scope in these topics and keywords: health, comparison, research, multiple, metaanalysis, patients, hemodialysis, based, review, costeffectiveness, ...

ISSN: 1098-3015

Editorial: Elsevier Ltd

Category: Medicine (miscellaneous)

Indexation: verifiedScopus / SJR verifiedWeb of Science

Unclaimed profile — some fields may be incomplete.

open_in_new Portal NPD menu_book Guidelines NPD

schedule Datos CoP · solo campos en BD

SJR Impact Factor trending_up

1,856 Q1

H-index 138

Tasa de Aceptación pie_chart

23% Selectiva

Fuente Acceptance_Rate

Tiempo a publicación hourglass_top

NPD

Campo Sin dato

Coste de Publicación (APC) payments

NPD Open Access

Ruta Non-OA 0 €

Metrics

Campos Scimago / CoP — sin series inventadas

Scopus / SJR Web of Science

SJR Impact

1,856

H-index

138

Docs (year)

206

Docs 3y

673

Total refs

9230

Cites 3y

2864

Citable 3y

602

Cites/Doc 2y

4.22

Ref/Doc

44.81

Immediate OA

—

Embargoed OA

NPD

Non OA / Submission

0 €

shield Researcher voice

Name good journals. Call out predatory ones.

Share what peer review, fees, and timelines were really like. Praise fair editors. Flag APC traps, fake metrics, or spam solicitations — with facts from your submission.

Fair & fast peer review Clear APC / no surprise fees Suspected predatory Fake impact claims

rate_review Write an honest review

Researcher reviews

sentiment_dissatisfied No reviews yet — be the first to share an honest experience.

Publication speed *

Review quality *

Edition and editorial team *

Institutional email or ORCID * * Only to validate authenticity — identity is not shown publicly.

Best articles by citations

CV6: ECONOMIC EVALUATION OF DALTEPARIN, ENOXAPARIN AND UNFRACTIONATED HEPARIN IN THE TREATMENT OF DEEP VEIN THROMBOSIS

Validation of the Revised 10-Item HIV Treatment Satisfaction Questionnaire Status Version and New Change Version

HP4: ASSESSING LIFESTYLE DRUGS FOR DRUG BENEFIT FORMULARIES: A COST-UTILITY ANALYSIS OF ORLISTAT AND SIBUTRAMINE FOR THE TREATMENT OF OBESITY IN ADULTS

HP3: INCORPORATING CLINICAL OUTCOMES AND ECONOMIC CONSEQUENCES INTO DRUG FORMULARY DECISIONS: EVALUATION OF 30 MONTHS OF EXPERIENCE

HP2: THE ROLE OF OUTLIER PAYMENTS IN MEDICARE PATIENTS WITH SEVERE SEPSIS

HP1: ETHNIC DISPARITY OF COMBINATION RIBAVIRIN/INTERFERON ALFA-2B PRESCRIBING AMONG HEPATITIS C-INFECTED MEMBERS IN A MANAGED CARE ORGANIZATION (MCO)

EM4: CAN UNIT COSTS BE COMPARED ACROSS WESTERN EUROPEAN COUNTRIES?

EM3: RESPONSE BIAS AMONG LIKELY CLINICAL TRIAL PARTICIPANTS

EM1: RISK ATTITUDE: ASSOCIATION WITH MAGNITUDE OF RISK AND PATIENT CHARACTERISTICS

DG4: DISEASE SEVERITY DETERMINES COST OF GASTROESOPHAGEAL REFLUX DISEASE IN A MIDWEST USA HEALTH CARE PLAN

DG3: A RETROSPECTIVE EVALUATION OF NONSTEROIDAL ANTI-INFLAMMATORY DRUG-INDUCED GASTROINTESTINAL COMPLICATIONS AMONG ADULTS IN A MANAGED CARE HEALTH PLAN

DG1: THE RELATIONSHIP OF DIABETES SYMPTOMS AND HEALTH-RELATED QUALITY OF LIFE

SHOW MORE ARTICLES

CV8: WORK-RELATED OUTCOMES OF PATIENTS SIX MONTHS AFTER MYOCARDIAL INFARCTION

A Comprehensive Strategy for the Interpretation of Quality-of-Life Data Based on Existing Methods

CV5: THE COST-EFFECTIVENESS OF LIFETIME FACTOR VIII PROPHYLAXIS IN THE TREATMENT OF SEVERE HEMOPHILIA A

CV4: USING UK OBSERVATIONAL DATA TO IDENTIFY POSSIBILITIES FOR THE COST-EFFECTIVE IMPROVEMENT OF THE TREATMENT OF ATRIAL FIBRILLATION

CV2: INDIRECT COMPARISONS OF DRUGS USING META-ANALYSIS: VALIDATION OF RESULTS

CV1: THE VALUE OF COMPLIANCE: EVIDENCE FROM TWO PATIENT COHORTS

Cost Sharing of Disease-Modifying Treatments (DMTs) as Policy Lever to Improve DMTs' Access in Multiple Sclerosis

CN4: ECONOMIC EVALUATION OF GEMZAR/CISPLATIN RELATIVE TO OTHER CISPLATIN BASED TREATMENTS FOR NON SMALL CELL LUNG (NSCLC) CANCER IN THE UK

CN3: COST-EFFECTIVENESS ANALYSIS OF IRINOTECAN+5FU/FA ALONE AS FIRST-LINE THERAPY IN ADVANCED COLORECTAL CANCER IN THE UK

CN2: EFFECT OF INCLUDING (VERSUS EXCLUDING) FATES WORSE THAN DEATH ON UTILITY MEASUREMENT

CN1: UTILITIES OF METASTATIC BREAST CANCER PATIENTS (PT) TREATED WITH TAXANES COMPARED TO UTILITIES OF ONCOLOGY NURSES (NUR)

Clinical and Economic Outcomes of Coronary Angioplasty Alone or in Combination with Stents in Academic Health Centers: A Retrospective Database Analysis

FAQS

In Country of Papers you can find SJR impact factor and other metrics to help you decide on a Journal.